The global in-vitro colorectal cancer screening tests market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising cases of rectal and colon cancer along with the wide use of novel screening tests with genetic testing.
Colorectal cancer, also called bowel cancer and colon cancer, is a type of cancer that affects the colon and the rectum by uncontrolled and abnormal division of cells leading to the formation of a malignant tumor. In-vitro colorectal cancer, screening tests are done to check symptoms and presence of colorectal cancer. In this test, the detection of colorectal cancer in patients is confirmed by understanding the progression and nature of this cancer. Increasing adoption of unhealthy food habits such as rising consumption of alcohol and tobacco smoking are responsible for inflammatory intestinal conditions, which lead to rising cases of colorectal cancer.
As per a global health report, colorectal cancer is one of the most common forms of cancer that accounts for nearly 10% of all global cancer incidences. These incidences are rising over the last few years. One of the key aspects of the market growth can be attributed to gradually introduction of the novel colorectal tests. These tests either use biomarkers such as tumor M2-PK marker or methylated genes for screening colorectal cancer. A major factor responsible for the market expansion is due to high accuracy of screening and diagnostic procedures, which are offered by these new genetic tests.
The report on the global in-vitro colorectal cancer screening tests market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
In-Vitro Colorectal Cancer Screening Tests Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Tumor M2-PK Stool Test, Transferrin Assays, Methylated Gene Testing, and Panel DNA Tests) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott Molecular, Beckman Coulter, Alere, Epigenomics, Eiken Chemical, Sysmex, Siemens Healthcare, Quest Diagnostics, Companion Dx, Oncocyte, Merck Millipore, Immunostics, ExiQon, Kyowa Medex, Mode Diagnostics, Randox Laboratories, and R-Biopharm |
Fecal occult blood tests segment is projected to hold a major market share
On the basis of products, the in-vitro colorectal cancer screening tests market is divided into fecal occult blood tests, biomarker tests, CRC DNA screening tests, guaiac FOB stool test, immuno-FOB agglutination test, lateral flow immuno-FOB test, immuno-FOB ELISA test, tumor M2-PK stool test, transferrin assays, methylated gene testing, and panel DNA tests.
The fecal occult blood tests segment is expected to dominate the market during the forecast period due to their increasing use and easy applicability to large number of populations at once. Meanwhile, the immuno-FOB ELISA and immuno-FOB agglutination test segment in combined accounted for a major share of the in-vitro colorectal screening tests market. However, the DNA and biomarker screening tests are the new tests with more accuracy for in-vitro colorectal cancer screening tests. Due to which, the segments are likely to register a high CAGR during the forecast period.
The transferrin assays and methylated gene testing segments are latest developments in the screening tests. In early stages of cancer and before the tumors spread inside human body, using transferrin assays gives valuable information in the screening of precancerous wound. Moreover, the transferrin dipstick test shows accuracy consistent with immuno-FOB stool tests. This is projected to boost the segment growth during the forecast period. Furthermore, the methylated gene testing is also widely adopted due to the prevalence of excessive risk of presence of colorectal cancer.
Asia Pacific is expected to dominate the market
On the basis of regions, the in-vitro colorectal cancer screening tests market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing number of colorectal cancer cases and larger geriatric population base in the region.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising occurrence of cancer in this region. Over the past decades, the death rate of colorectal cancer has been increasing in this region. National guidelines on colorectal cancer screening are formally adopted in countries such as South Korea, Taiwan, Japan, and Singapore. This leads to the rapid expansion of the market in the region.
Key players competing in the in-vitro colorectal cancer screening tests market include Abbott Molecular, Beckman Coulter, Alere, Epigenomics, Eiken Chemical, Sysmex, Siemens Healthcare, Quest Diagnostics, Companion Dx, Oncocyte, Merck Millipore, Immunostics, ExiQon, Kyowa Medex, Mode Diagnostics, Randox Laboratories, and R-Biopharm.
Some of these key players are majorly focusing on collaboration strategy to increase product portfolio. Moreover, they are actively investing on R&D for the development of CRC DNA and biomarker screening tests along with other business strategies such as mergers, acquisitions, partnerships, and capacity expansion to increase their market shares.
Some other reports from this category!